Company intelligence / Profile preview
Carephar
Nanjing, Jiangsu, Chinacarephar.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Carephar has achieved commercial approval in China for keverprazan hydrochloride for duodenal ulcer and reflux esophagitis. The company has multiple innovative drugs in clinical and preclinical stages across cardiovascular, cerebrovascular, digestive diseases, oncology/immunotherapy, and chronic diseases. Its pipeline includes small molecules, stem cell therapies, and traditional Chinese medicines with several programs in late-stage clinical development or approved status.
- Therapeutic areas
- GastroenterologyMen's HealthInfectious Diseases
- Modalities
- Small moleculeMesenchymal stem cell therapyTraditional Chinese medicineChemical drugBiologic
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
Fosun Pharma – global co-development and exclusive commercialization partnership for Keverprazan Hydrochloride
Beyond the preview
Go deeper on Carephar.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carephar.